Efficacy and safety of lifileucel, an investigational autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma previously treated with anti-LAG3 antibody

Category Primary study
JournalAnnals of Oncology
Year 2022
This article has no abstract
Epistemonikos ID: 41595320328cb10a43627f2c393e8277c61befa7
First added on: Feb 15, 2025